In explaining why some patients who switch to biosimilars from reference biologics discontinue their therapy at a higher rate than those who remain on a therapy without interruption, some authors have referenced the so-called “nocebo” effect. This effect, whereby a patient experiences disease worsening or adverse events due to negative beliefs about a drug, has been controversial, however, and not all clinicians agree that the effect is to blame for differences in discontinuation.
In explaining why some patients who switch to biosimilars from reference biologics discontinue their therapy at a higher rate than those who remain on a therapy without interruption, some authors have referenced the so-called “nocebo” effect. This effect, whereby a patient experiences disease worsening or adverse events (AEs) due to negative beliefs about a drug, has been controversial, however, and not all clinicians agree that the effect is to blame for differences in discontinuation.
Read more about the nocebo effect and biosimilars.
A newly published review sought to investigate the nocebo effect; the review’s authors assessed studies reporting the efficacy and safety outcomes of a switch from a reference drug to an FDA-approved biosimilar. A total of 31 trials were included; 28 involved infliximab, and 3 involved etanercept. Among these studies, only 2 studies of infliximab were double-blinded randomized controlled trials (RCTs), and 2 publications on etanercept evaluated different time points of the same double-blinded RCT.
Results for 3271 patients were reported in total. The most common indications for treatment were inflammatory bowel disease, rheumatoid arthritis, and psoriasis. The mean followup after a switch to a biosimilar was 48 weeks (range, 16-80 weeks).
The analysis revealed that the median discontinuation rates for any reason were 14.3% in open-label studies (range, 0.0%-33.3%) versus 6.95% in double-blinded RCTs (range, 5.2%-11.0%). Discontinuation rates resulting from AEs were 5.6% in open-label studies (range, 0.0%-24.2%) versus 3.1% (range, 2.0%-5.2%) in double-blinded RCTs. A subgroup analysis revealed that antidrug antibody development and infusion reactions were similar between patients in open-label and double-blind RCTs of infliximab.
“Some evidence from the comparison of biosimilar discontinuation rates supports the hypothesis that this outcome measure is highly susceptible to the nocebo effect,” write the authors, but they add that “current evidence is insufficient to confirm a biosimilar nocebo effect.” More studies will be needed to evaluate whether the nocebo effect does in fact impact patients who switch to biosimilars and to identify mitigation strategies—such as patient education—that could help to overcome such an effect.
However, the authors point out that provider education may well play a role in mitigating a nocebo effect, if indeed it is present. Physicians’ knowledge gaps around biosimilars or hesitancy to use these agents may either create or reinforce patients’ negative expectations, so appropriate framing of discussions about biosimilars will be key.
Reference
Odinet JS, Day CE, Cruz JL, Heindel GA. The biosimilar nocebo effect? A systematic review of double-blinded versus open-label studies. J Manag Care Spec Pharm. 2018;24(10):952-959. doi: 10.18553/jmcp.2018.24.10.952.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.
13 Strategies to Avoid the Nocebo Effect During Biosimilar Switching
December 18th 2024A systematic review identified 13 strategies, including patient and provider education, empathetic communication, and shared decision-making, to mitigate the nocebo effect in biosimilar switching, emphasizing the need for a multifaceted approach to improve patient perceptions and therapeutic outcomes.